| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
Time-blocked inhibition of IGF2 expression in Hep3B TS cells is observed with chromeceptin (94G6) (5 μM) [1]. Rapamycin (mTOR) and protein regulatory B (AKT, Ser463 of AKT, TS cells) are both decreased by chromececeptin. The phosphorylation of the ser371 site in the mTOR effector ribosomal protein S6 rest (p70S6K) is inhibited by chromeceptin [1].
|
|---|---|
| References |
[1]. Seol HS, et al. Loss of miR-100 and miR-125b results in cancer stem cell properties through IGF2 upregulation in hepatocellular carcinoma. Sci Rep. 2020 Dec 8;10(1):21412.
|
| Molecular Formula |
C19H16F3N3O
|
|---|---|
| Molecular Weight |
359.3522
|
| Exact Mass |
359.12
|
| Elemental Analysis |
C, 63.51; H, 4.49; F, 15.86; N, 11.69; O, 4.45
|
| CAS # |
331859-86-0
|
| Related CAS # |
331859-86-0
|
| Appearance |
Solid powder
|
| SMILES |
CN(C)C1=CC2=C(C=C1)C(C(=C(O2)N)C#N)C3=CC(=CC=C3)C(F)(F)F
|
| InChi Key |
GVINXTXGDDSXFQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H16F3N3O/c1-25(2)13-6-7-14-16(9-13)26-18(24)15(10-23)17(14)11-4-3-5-12(8-11)19(20,21)22/h3-9,17H,24H2,1-2H3
|
| Chemical Name |
2-amino-7-(dimethylamino)-4-[3-(trifluoromethyl)phenyl]-4H-chromene-3-carbonitrile
|
| Synonyms |
94G6; Chromeceptin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~278.3 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 10 mg/mL (27.83 mM) in 50% PEG300 +50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7828 mL | 13.9140 mL | 27.8280 mL | |
| 5 mM | 0.5566 mL | 2.7828 mL | 5.5656 mL | |
| 10 mM | 0.2783 mL | 1.3914 mL | 2.7828 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
